Hartwig Medical Foundation welcomes Eliëtte Vaal to its Supervisory Board
Hartwig Medical Foundation (Hartwig) has welcomed Eliëtte Vaal as a new member of its Supervisory Board. Her appointment reflects Hartwig’s proactive response to developments in legislation and regulations concerning the (re)use of sensitive patient data to improve cancer care. Eliëtte brings extensive expertise in data, AI, and privacy law, which is a valuable addition to the Board.
Her arrival coincides with the departure of Guido Derckx, partner at Loyens & Loeff, who stepped down on 1 April after serving on the Board since Hartwig’s founding in 2015. His commitment and legal insight have been instrumental in strengthening the professionalism of the Supervisory Board. Hartwig expresses its sincere gratitude for his many years of dedicated service.
Data-driven cancer care
Constantijn van Oranje, chair of Hartwig’s Supervisory Board: ‘Hartwig has evolved from a high-tech laboratory into a data- and software-driven organization, leveraging sensitive patient data to advance cancer care. This transformation calls for specific expertise on our Supervisory Board. We are therefore pleased to welcome Eliëtte Vaal. Her legal knowledge and experience in complex data privacy and regulatory matters will be of great value in this phase. It is essential to achieve our goal: better, data-driven cancer care for every patient.’
Building trust
Eliëtte Vaal: ‘It is a great opportunity to apply my legal expertise to support Hartwig’s ambitions and the legal challenges it faces, and to contribute to improving care for cancer patients. The responsible and secure use of data is crucial for personalized treatments and for accelerating research. By collecting, using, and sharing patient data in a responsible and transparent way, we can not only enhance the effectiveness of treatments, but also strengthen patients’ trust in data-driven healthcare.’
About Eliëtte Vaal
Eliëtte Vaal is a partner and co-founder of The Data Lawyers, specializing in AI, privacy, and IT law. She advises and litigates on data-related legal matters and has broad experience within the healthcare sector. Eliëtte also serves on the European Advisory Board of the International Association of Privacy Professionals (IAPP), is a member of the Board of Directors of claim foundation CUIC, an Arbiter at SGOA, and a member of the Advisory Board of the Privacy First Foundation.
All news
Also read
Collaboration as the foundation for faster, better, and more affordable diagnostics
For Kees van den Berg, the CEO of GenomeScan, the collaboration between his organization and the Hartwig Medical Foundation is …
Clinical Cancer Genomics 2025: a cheerful boost for this rapidly emerging field
The Clinical Cancer Genomics Conference 2025 took place on 20–21 March 2025 in Amsterdam. The event website ccg2025.eu has been retired, but …
Hartwig Medical Foundation adapts working method and continues work
In this uncertain time when we are trying to prevent the spread of the Coronavirus, we have adapted our working …
Cancer is caused by DNA mutations. There are an increasing number of drugs available that act on specific errors in the DNA of an individual patient’s tumor. A drug that doesn’t fit, like a key in a lock, will not work, while the risk of side effects remains.